ISOgenix

Medical AI

Overview

Developing precision medicines by harnessing the power of protein isoforms. Using a proprietary approach, we are identifying and developing precision therapies to harness the therapeutic potential of protein isoforms, with an initial focus on neuromuscular and neurological diseases.

Funding and backers

Latest round
Venture round
Aug 2026 · 3 mo ago
Backers
1
Oxford Science Enterprises
The money's age
Fresh money
3 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 4 Raised a round Venture round Apr 6, 2023 Raised a round Venture round 2023 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Aug 2026 — — find-and-update.company-information.service.gov.uk
Venture round Apr 2023 — — find-and-update.company-information.service.gov.uk
Registers and programsofficial lists and records that name the company
Legal entity Isogenix Limited its site
Backed byfrom the funds' portfolios and accelerator catalogs
Oxford Science Enterprises fund
Investors in similar startupsfunds that back the companies most like this one
Kleiner Perkins
backs Neuron23
Pear VC
backs Atrix AI
UCL Technology Fund
backs Nanomerics
Airstreet
backs Gandeeva
Precursor Ventures
backs Atrix AI
Obvious Ventures
backs Gandeeva
Similar startupsby what they do, their industry and backers
MOMA Therapeutics
We will discover the next generation of precision medicines by targeting the molecular machines that underlie human disease.
Nanomerics
Engineering Precision Medicines. Developing targeted therapies that address serious medical need using proprietary platform technologies…
Atrix AI1 role
Atrix AI helps Medical Affairs, Commercial, Clinical, and Regulatory teams unlock the potential of their data to drive strategic outcomes…
Decoded11-50 employees
The power of Fusion: AI (artificial intelligence) + HI (human intelligence). Let the power of Clinically trained Artificial Intelligence…
Neuron23Series D $96.5M · 16 mo ago
Neuron23 is developing a precision medicine approach designed to improve the lives of people with Parkinson’s disease.
Chief AiVenture round · 7 mo ago · Founded 2018
Chief.AI elevates your data and generates novel AI models and algorithms to enable precision medicine and personalised treatments.

Financials

Latest round
Venture - Series Unknown
Funding rounds
2
Funding rounds
Round Announced Amount
Venture - Series Unknown 2026 — Details
Venture - Series Unknown 2023 — Details

Connections

List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Owner
1
confirmed by a register
Shared investors
1
Owner1
Oxford Science EnterprisesConfirmed
oxfordscienceenterprises.com
UK PSC: controlling company
seen Nov 1, 2026 · evidence: 1 Show evidence
Shared investors1
Oxford Science EnterprisesVia a fund
81 portfolio companies: First Light Fusion, Archangel Lightworks, Alloyed and 78 more
Report a mistake